Member Info for Marty130

So we're still on course for the histology and MC data, in June/July. Our anniversary on the 16th of July, what a present that would be, witnessing a rerating of this stock to the upper 9s or more.

No, I did read PP post with admiration. The IP will be the game changer. Onwards and upwards.

So from I read into what Eric was saying, we can't expect any news until October, although we had previously been told histology and MC data was to be ready by July..

I imagine the market won't like it and we can look to see a reduction in value.

👍

I am OK, just keen to see this moving forward, conformation of my original decision to invest was indeed the correct one.

Still waiting on the MC and histology results.

The BoD are waiting for the patent to be granted before anything significant can be legally announced.

True and not as old as me, 60s.

Where's PP?

Genflow Biosciences PLC Announces Participation at BIO International Convention 2026

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Tags

Rhea-AI Summary

Genflow Biosciences (OTCQB:GENFF) announced that Independent Non-Executive Chairman Gad Berdugo will attend the BIO International Convention 2026 in San Diego from June 22-25.

He will speak on an RNA therapeutics panel focused on technical advances and clinical validation over the next 3-5 years.

AI-generated analysis. Not financial advice.

Don't miss StockTitan's market coverage in Google Search and AI answers.

Add on Google

Not now

22/06/2026 - 07:00

LONDON, UK / ACCESS Newswire / June 22, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, today announces Gad Berdugo, Independent Non-Executive Chairman will attend the BIO International Convention June 22-25 in San Diego, California.

Mr. Berdugo will participate in the panel discussion titled: "RNA Therapeutics: Where Will We See the Greatest Technical Advances and Continued Clinical Validation in the Next 3-5 Years?"

The BIO International Convention is one of the world's largest biotechnology industry events, bringing together biotechnology companies, academic and research institutions, investors, policymakers and industry leaders from across the globe to discuss scientific innovation, emerging technologies and the future of healthcare.

6p is realistic, on good news.

No, I'm in for the long term, upto 3 year's, as long as it takes. I would feel much more comfortable to see higher volumes and share price.

What are your expectations on a future share price on receipt of good news. I for one believe a jump to 6p is very likely, with steady rises in the coming weeks..

Genflow plc possibly share price re rate +9 Genflow Biosciences PLC (LSE:GENF) is a preclinical biotechnology company developing gene therapies for age-related diseases. The stock trades on the London Stock Exchange (LSE) and is currently priced between 2.05p and 2.15p, with a market capitalization of approximately £11.78M.Current Share Price & PerformanceLast Traded/Current Price: 2.05p - 2.15p52-Week Range: 0.55p to 3.12pMarket Capitalization: ~£11.78 millionYear-to-Date (YTD): GENF is up ~12–16%, though short-term volatility remains.Potential Catalysts for a Re-RatingThe market's valuation of a pre-revenue biotechnology company typically shifts ("re-rates") based on clinical milestones, IP expansion, and commercial partnerships. Key drivers for Genflow include:Canine Longevity Trials: The company has reported promising interim safety and efficacy data from its SIRT6 gene therapy trial in aged dogs. Continued positive data could trigger a major re-rate as it validates the technology platform in large animals.Corporate Partnerships: Genflow has expanded confidentiality agreements with major global animal health companies and established delivery deals. Entering into definitive development or licensing agreements would provide non-dilutive capital and commercial validation.Pipeline Progress: Progression of its flagship human compound, GF-1002 (targeting the SIRT6 variant to slow the aging process), into further stages of development.Cash Runway: Biotech re-ratings are closely tied to liquidity. The company successfully raised £800,000 and confirmed receipt of a €4 million grant installment to fund ongoing programs.You can track real-time price movements and view official announcements using Yahoo Finance UK, the London South East platform, or via the London Stock Exchange.Would you like me to dive deeper into Genflow's financial runway, the specifics of their SIRT6 gene therapy, or the competitive landscape for age-related biotech?Genflow Biosciences plc (GENF.L) latest stock news and headlinesGenflow Biosciences plc (GENF. L) * Genflow surges 14% as animal health giants circle canine ageing gene therapy. ... * Genflow widens confidentiality agreement...Yahoo Finance UKGenflow Biosciences plc (GENF.L)GENF.L. Genflow Biosciences plc. 2.0800. +0.24% Mkt cap GBp 11.781M. Industry Biotechnology. CIZ.L. Cizzle Biotechnology Holdings Plc. 2.7000. -5.26% Mkt cap GB...Yahoo Finance UKGenflow Biosciences Share Price | GENF StockWhat Is the Genflow Biosciences PLC Share Price Today? The Genflow Biosciences share price today is 2.08. What Is the Stock Symbol for Genflow Biosciences PLC. ...Investing.com UKGenflow Biosciences Share Price Forecast (GENF)

Let's hope you're right..

Going down, hi time something was done to increase volume and hopefully arrest the price drop.

EL stated back in February results were two months away. Didn't happen so what's gone wrong?

Cognition Therapeutics secu...

AlzeCure clears key hurdle ...

Resolution Therapeutics ext...

ProJenX completes enrollmen...

Qihan Biotech cell therapy ...

Cognition Therapeutics secu...

AlzeCure clears key hurdle ...

Resolution Therapeutics ext...

ProJenX completes enrollmen...

Qihan Biotech cell therapy ...

Biotech

Feb 12, 2026

Genflow reveals early data from SIRT6 gene therapy trial in dogs

Danny Sullivan

Preliminary results indicate that treated animals demonstrated ‘superior survival’ and functional improvements compared to the control group.

It’s a good week to be a dog. Hot on the heels of Loyal raising $100m to gear up for commercialization of its canine longevity drug, longevity biotech Genflow Biosciences today announced preliminary interim findings from a clinical study evaluating its SIRT6 gene therapy in aged dogs. The London-based company, founded in 2020 to develop gene therapies targeting age-related disease, sees the program as both an opportunity in companion animal health and a stepping stone toward human applications.

The SIRT6 gene has attracted significant attention in the longevity field because of its role in DNA repair and genome stability, and research indicating that enhancing its activity may influence lifespan and resilience in animal models. By first applying its technology in companion animals, Genflow hopes to build clinical evidence that could also inform human therapeutic development.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Email Address(Required)

Enter Your Email Address

CAPTCHA

Today’s data come from the SLAB (Sarcopenia and Longevity in Aged Beagles) trial, where 24 beagles aged 10 years or older were enrolled and assigned across four groups, including two naked DNA treatment cohorts at different dose levels, a single-dose AAV8 cohort, and an untreated control arm. The proof-of-concept study was first announced last year and focuses on assessing whether delivery of a variant of the SIRT6 gene can mitigate functional decline associated with aging.

According to the interim analysis announced by Genflow today, all treatment groups showed “superior survival” compared with the control animals during the dosing period. Beyond survival outcomes, the company says that treated animals displayed improvements across several functional indicators, including quality of life measures, maintenance of muscle mass, reductions in frailty scores and visible changes such as coat condition. Control animals followed a more typical trajectory of age-related decline.

Dr Eric Leire, founder and CEO of Genflow Biosciences

“The consistency of positive signals across multiple independent endpoints from survival and quality of life to measures of muscle preservation and frailty reduction, combined with an excellent safety profile, supports our SIRT6 platform as a credible, differentiated asset for the companion animal market,” said Genflow C

So we're left to assume the results, although, not ready just yet, will be showing good efficacy..

FCA rules require companies to release test results immediately if they qualify as inside information under the UK Market Abuse Regulation (MAR). Test results—such as clinical trials, operational tests, or product performance milestones—must be published without delay if they are precise, non-public, and would likely have a significant impact on share prices.Key FCA RequirementsThe Test of "Precision": Information is considered precise if it indicates a set of circumstances or an event that exists or may reasonably be expected to come into existence, provided it is specific enough to enable a conclusion to be drawn.The "Price Sensitivity" Test: If a reasonable investor would be likely to use the test results as part of the basis of his or her investment decisions (i.e., it would significantly move the stock), it must be disclosed.No Selective Disclosure: Companies cannot share these results with analysts, institutional investors, or journalists before they are released to the wider public. Test results must be announced via a Regulatory Information Service (RIS).Delaying DisclosureUnder Article 17(4) of MAR, a company may temporarily delay the disclosure of test results to avoid prejudicing its legitimate interests (e.g., if the information is part of an incomplete, protracted negotiation).However, all three of the following conditions must be met for a delay to be valid:Immediate disclosure is likely to prejudice the legitimate interests of the issuer.Delay of disclosure is not likely to mislead the public.The issuer is able to ensure the confidentiality of that information.If the information leaks or confidentiality is breached during the delay, the company must issue a public announcement immediately. Furthermore, whenever a company decides to delay the disclosure of inside information, it must notify the FCA upon releasing the information and be prepared to provide a written explanation of how the conditions for delay were met.